Entering text into the input field will update the search result below

AstraZeneca to acquire blood cancer drug maker TeneoTwo for $100M upfront

Jul. 05, 2022 4:30 AM ETAstraZeneca PLC (AZN)By: Ravikash, SA News Editor1 Comment

AstraZeneca production plant

Roland Magnusson/iStock Editorial via Getty Images

  • AstraZeneca (NASDAQ:AZN) is acquiring U.S.-based blood cancer drug maker TeneoTwo for $100M upfront plus milestone payments.
  • The British pharma giant will acquire all outstanding equity of TeneoTwo, a majority owned unit of Delaware-based TBio, for an upfront $100M on deal closing

Recommended For You

Comments (1)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

biogenius profile picture
T cell engager rather than CART? Another example of BP buying on the cheap?

About AZN

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
AstraZeneca PLC
Roche Holding AG
Pfizer Inc.
Merck & Co., Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.